Article
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.
Scientific reports - 10 Nov 2017
Fischer Marcus M, Yeung V Pete, Cattaruzza Fiore, Hussein Rajaa, Yen Wan-Ching, Murriel Christopher, Evans James W, O'Young Gilbert, Brunner Alayne L, Wang Min, Cain Jennifer, Cancilla Belinda, Kapoun Ann, Hoey Timothy
Abstract excerpt
Activating mutations in the Wnt pathway are a characteristic feature of colorectal cancer (CRC). The R-spondin (RSPO) family is a group of secreted proteins that enhance Wnt signaling and RSPO2 and RSPO3 gene fusions have been reported in CRC. We have previously shown that Wnt pathway blockers exhibit potent combinatorial activity with taxanes to inhibit tumor growth. Here we show that RSPO3 antagonism synergizes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.